Inclusion Criteria:  Informed Consent as documented by a signature and date of the patient Age 18-85 years Acute NSTEMI as anticipated to be type 1 (expert opinion by the cardiologist before coronary angiography) and scheduled for urgent coronary angiography Documented kidney disease existing for ≥3 months OR Two estimated glomerular filtration rate (eGFR) measurements of <60ml/min/1.73m2 as calculated by the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) study equation and at least 6 hours apart OR eGFR of <50 mL/min//1.73m2 as calculated by using the CKD-EPI study equation at presentation At least one of the following risk factors for AKI: diabetes mellitus, age >60 years, established cardiovascular disease, heart failure with reduced ejection fraction, anemia  Exclusion Criteria:  Contraindications to the class of drugs under study (C1 esterase inhibitors), e.g. known hypersensitivity or allergy to class of drugs or the IMP History or suspicion of allergy to rabbits Women who are pregnant or breast feeding ST elevation myocardial infarction or unstable angina Cardiogenic shock requiring mechanical support Non-cardiac comorbidity with expected survival <6 months Acute urinary tract infection (e.g. cystitis, pyelonephritis). Liver cirrhosis (any Child-Pugh score) Dialysis or eGFR <20 and >59mL/min/1.73 m2 at baseline (d0) Incapacity or inability to provide informed consent Participation in another study with investigational drug within 30 days preceding, and during the present study Previous enrolment into the current study